Some studies have demonstrated the role of HER2 antibody in promoting anti-cancer immune activities (60), leading to the logical attempt to add anti-HER2 treatment to ICI in EC, which brings us the well-known clinical trials such as KEYNOTE-811 and MAHOGANY studies. The gene discussed is ERBB2; the disease is cancer.